{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:04:07Z","timestamp":1777482247771,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      M5A is a humanized monoclonal antibody (mAb) directed against carcinoembryonic antigen (CEA) The purpose of this first in human phase I dose-escalation trial was to characterize the toxicities and determine the maximum tolerated dose (MTD) of yttrium-90 (\n                      <jats:sup>90<\/jats:sup>\n                      Y)-DOTA-M5A as a single agent and in combination with gemcitabine (gem).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Patients with advanced metastatic CEA-producing malignancies who had progressed on standard therapies were first administered indium-111 (\n                      <jats:sup>111<\/jats:sup>\n                      In)-DOTA-M5A. If tumor targeting was observed, the patient then received the therapy dose of\n                      <jats:sup>90<\/jats:sup>\n                      Y-DOTA-M5A. Serial scans, blood sampling, and 24\u2009h urine collections were then performed to estimate radiation doses to organs and total body. Assays for human antihuman antibody (HAHA) responses were performed out to 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 18 patients who received\n                      <jats:sup>111<\/jats:sup>\n                      In-DOTA-M5A, 16 received\n                      <jats:sup>90<\/jats:sup>\n                      Y-DOTA-M5A therapy; 1 patient at 14 mCi\/m\n                      <jats:sup>2<\/jats:sup>\n                      with gem (150\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      days 1and 3), 3 patients at 12 mCi\/m\n                      <jats:sup>2<\/jats:sup>\n                      with gem, 6 patients at 12 mCi\/m\n                      <jats:sup>2<\/jats:sup>\n                      without gem, and 6 at 10 mCi\/m\n                      <jats:sup>2<\/jats:sup>\n                      without gem. Prolonged cytopenias resulted in discontinuation of dose escalation with gemcitabine. A single agent MTD of 10 mCi\/m\n                      <jats:sup>2<\/jats:sup>\n                      was established based on dose-limiting hematopoietic toxicities. HAHA immune response was identified in 2 of 16 patients (12.5%). Stable disease at 3 months was seen in 10 patients and 2 patients demonstrated an 88% and 64% decrease in CEA back to normal levels. In 2 patients\n                      <jats:sup>111<\/jats:sup>\n                      In-DOTA-M5A imaging revealed previously unknown brain metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      This study demonstrates the potential utility of the\n                      <jats:sup>90<\/jats:sup>\n                      Y-DOTA-M5A anti-CEA mAb as a therapeutic antibody. There is decreased immunogenicity compared with murine and chimeric mAbs, allowing for the potential of multiple administrations. Combined modality therapy approaches incorporating this agent should continue to be evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cbr.2019.2992","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T17:22:25Z","timestamp":1578417745000},"page":"10-15","source":"Crossref","is-referenced-by-count":14,"title":["Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies"],"prefix":"10.1177","volume":"35","author":[{"given":"David","family":"Akhavan","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Yazaki","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapy, Beckman Research Institute, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, City of Hope National Cancer Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope National Cancer Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[{"name":"Department of Information Sciences, City of Hope National Cancer Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Bading","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapy, Beckman Research Institute, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Colcher","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapy, Beckman Research Institute, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kofi","family":"Poku","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapy, Beckman Research Institute, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-jen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope National Cancer Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope National Cancer Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapy, Beckman Research Institute, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Shively","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapy, Beckman Research Institute, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey Y.C.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000276"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.040"},{"key":"e_1_3_4_4_2","first-page":"5842","article-title":"A phase I trial of Y-90-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer","volume":"9","author":"Wong JYC","year":"2003","unstructured":"Wong JYC, , Shibata S, , Williams LE, et al. A phase I trial of Y-90-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res, 2003; 9:5842.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2213"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.119"},{"key":"e_1_3_4_7_2","first-page":"517","article-title":"Toxicity and efficacy of combined radioimmunotherapy and bevacizumab (avastin) in mouse model of medullary thyroid carcinoma [abstr]","volume":"23","author":"Bodet-Milin C","year":"2008","unstructured":"Bodet-Milin C, , Salaun P-Y, , Paris F, et al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab (avastin) in mouse model of medullary thyroid carcinoma [abstr]. Cancer Biother Radiopharm, 2008; 23:517.","journal-title":"Cancer Biother Radiopharm"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1134\/S0026893317060115"},{"key":"e_1_3_4_9_2","first-page":"2128","article-title":"Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human\/mouse T84.66 genes in myeloma and Chinese hamster ovary cells","volume":"50","author":"Neumaier M","year":"1990","unstructured":"Neumaier M, , Shively L, , Chen FS, et al. Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human\/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. Cancer Res, 1990; 50:2128.","journal-title":"Cancer Res"},{"key":"e_1_3_4_10_2","first-page":"6494","article-title":"Pre-operative imaging of colorectal carcinoma with 111-In-labled anti-carcinoembryonic antigen monoclonal antibody","volume":"46","author":"Beatty JD","year":"1986","unstructured":"Beatty JD, , Duda RB, , Williams LE. Pre-operative imaging of colorectal carcinoma with 111-In-labled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res, 1986; 46:6494.","journal-title":"Cancer Res"},{"key":"e_1_3_4_11_2","first-page":"1951","article-title":"Clinical evaluation of Indium-111-labeled chimeric anti-CEA monoclonal antibody","volume":"38","author":"Wong JYC","year":"1997","unstructured":"Wong JYC, , Thomas GE, , Yamauchi DM, et al. Clinical evaluation of Indium-111-labeled chimeric anti-CEA monoclonal antibody. J Nucl Med, 1997; 38:1951.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_12_2","first-page":"3855","article-title":"A Phase I radioimmunotherapy trials evaluating Y-90 labeled anti-CEA chimeric T84.66 in patients with metastatic CEA-producing malignancies","volume":"6","author":"Wong JYC","year":"2000","unstructured":"Wong JYC, , Chu DZ, , Yamauchi DM, et al. A Phase I radioimmunotherapy trials evaluating Y-90 labeled anti-CEA chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res, 2000; 6:3855.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2006.21.88"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzh056"},{"key":"e_1_3_4_15_2","first-page":"1951","article-title":"Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody","volume":"38","author":"Wong JY","year":"1997","unstructured":"Wong JY, , Thomas GE, , Yamauchi D, et al. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody. J Nucl Med, 1997; 38:1951.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_16_2","first-page":"213","article-title":"Bone marrow dosimetry and toxicity for radioimmunotherapy","volume":"3","author":"Siegel JA","year":"1990","unstructured":"Siegel JA, , Wessels BW, , Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm, 1990; 3:213.","journal-title":"Antibody Immunoconj Radiopharm"},{"key":"e_1_3_4_17_2","first-page":"1023","article-title":"OLINDA\/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin MG","year":"2005","unstructured":"Stabin MG, , Sparks RB, , Crowe E. OLINDA\/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 2005; 46:1023.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_18_2","first-page":"1099","article-title":"Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials","volume":"33","author":"Breitz HB","year":"1992","unstructured":"Breitz HB, , Weiden PL, , Vanderheyden JL, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med, 1992; 33:1099.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_19_2","first-page":"1017","article-title":"Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49","volume":"35","author":"Meredith RF","year":"1994","unstructured":"Meredith RF, , Bueschen AJ, , Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med, 1994; 35:1017.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_20_2","first-page":"1180","article-title":"Radioimmunotherapy for breast cancer using indium-111\/yttrium-90 BrE- 3: Results of a phase I clinical trial","volume":"38","author":"DeNardo SJ","year":"1997","unstructured":"DeNardo SJ, , Kramer EL, , O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111\/yttrium-90 BrE- 3: Results of a phase I clinical trial. J Nucl Med, 1997; 38:1180.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_21_2","first-page":"2729","article-title":"Phase I\/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma","volume":"4","author":"Divgi CR","year":"1998","unstructured":"Divgi CR, , Bander NH, , Scott AM, et al. Phase I\/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res, 1998; 4:2729.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_22_2","first-page":"23","article-title":"Phase I trial of iodine-131-chimeric B72.3 (Human IgG4) in metastatic colorectal cancer","volume":"33","author":"Meredith RF","year":"1992","unstructured":"Meredith RF, , Khazaeli MB, , Plott WE, et al. Phase I trial of iodine-131-chimeric B72.3 (Human IgG4) in metastatic colorectal cancer. J Nucl Med, 1992; 33:23.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_23_2","first-page":"2229","article-title":"Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer","volume":"36","author":"Meredith RF","year":"1995","unstructured":"Meredith RF, , Khazaeli MB, , Plott WE, et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med, 1995; 36:2229.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_24_2","first-page":"1745","article-title":"Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody","volume":"17","author":"DeNardo SJ","year":"1997","unstructured":"DeNardo SJ, , O'Grady LF, , Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res, 1997; 17:1745.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_25_2","first-page":"1999","article-title":"Phase I therapy study of 186re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck","volume":"41","author":"Colnot DR","year":"2000","unstructured":"Colnot DR, , Quak JJ, , Roos JC, et al. Phase I therapy study of 186re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med, 2000; 41:1999.","journal-title":"J Nucl Med"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2019.2992","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2019.2992","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2019.2992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:15:19Z","timestamp":1777385719000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2019.2992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1089\/cbr.2019.2992"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2019.2992","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}